Fekrvand, S. and Yazdani, R. and Olbrich, P. and Gennery, A. and Rosenzweig, S.D. and Condino-Neto, A. and Azizi, G. and Rafiemanesh, H. and Hassanpour, G. and Rezaei, N. and Abolhassani, H. and Aghamohammadi, A. (2020) Primary Immunodeficiency Diseases and Bacillus Calmette-Guérin (BCG)-Vaccine�Derived Complications: A Systematic Review. Journal of Allergy and Clinical Immunology: In Practice, 8 (4). pp. 1371-1386.
Full text not available from this repository.Abstract
Background: Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated bacterial vaccine derived from Mycobacterium bovis, which is mostly administered to neonates in regions where tuberculosis is endemic. Adverse reactions after BCG vaccination are rare; however, immunocompromised individuals and in particular patients with primary immunodeficiencies (PIDs) are prone to develop vaccine-derived complications. Objective: To systematically review demographic, clinical, immunologic, and genetic data of PIDs that present with BCG vaccine complications. Moreover, we performed a meta-analysis aiming to determine the BCG-vaccine complications rate for patients with PID. Methods: We conducted electronic searches on Embase, Web of Science, PubMed, and Scopus (1966 to September 2018) introducing terms related to PIDs, BCG vaccination, and BCG vaccine complications. Studies with human subjects with confirmed PID, BCG vaccination history, and vaccine-associated complications (VACs) were included. Results: A total of 46 PIDs associated with BCG-VAC were identified. Severe combined immunodeficiency was the most common (466 cases) and also showed the highest BCG-related mortality. Most BCG infection cases in patients with PID were reported from Iran (n = 219 18.8%). The overall frequency of BCG-VAC in the included 1691 PID cases was 41.5% (95% CI, 29.9-53.2; I2 = 98.3%), based on the results of the random-effect method used in this meta-analysis. Patients with Mendelian susceptibility to mycobacterial diseases had the highest frequency of BCG-VACs with a pooled frequency of 90.6% (95% CI, 79.7-1.0; I2 = 81.1%). Conclusions: Several PID entities are susceptible to BCG-VACs. Systemic neonatal PID screening programs may help to prevent a substantial amount of BCG vaccination complications. © 2020 American Academy of Allergy, Asthma & Immunology
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 3 |
| Uncontrolled Keywords: | BCG vaccine, Article; BCG vaccination; demography; disease association; disease classification; disease severity; drug fatality; drug safety; erythema; fever; genetics; hematopoietic stem cell transplantation; human; immune deficiency; infection sensitivity; Iran; laboratory test; lymphadenopathy; medical history; mortality rate; mycobacteriosis; newborn screening; rash; severe combined immunodeficiency; skin defect; skin nodule; skin ulcer; systematic review |
| Subjects: | QV Pharmacology QW Microbiology. Immunology |
| Depositing User: | eprints admin |
| Date Deposited: | 09 Sep 2020 06:50 |
| Last Modified: | 09 Sep 2020 06:50 |
| URI: | http://eprints.iums.ac.ir/id/eprint/23865 |
Actions (login required)
 |
View Item |
